Background and aims: Insulin resistance (IR) is a common pathogenic factor of several diseases: diabetes mellitus, the metabolic syndrome, arterial hypertension, atherosclerosis, dyslipidemia, etc. There are many therapeutic factors involved in decreasing IR. Among them we mention metformin, pioglitazone, physical activity, weight loss, diet, etc. In the last decade, there are more observations of the influence of polyunsaturated fatty acids on IR. The most powerful seem to be omega-3 fatty acids. In our study, we wanted to asses if the administration of omega-3 fatty acids is involved in modifying IR. Materials and methods: We evaluated 126 diabetic patients with IR from January 2011 until July 2014. The study was open-label and non-randomized. For the determination of IR we used the HOMA-IR method. Results: For both males and females there was a regression of HOMA-IR during the 4 weeks of treatment with omega-3 and also after 2 weeks after stopping the administration of these fatty acids. The decrease of HOMA-IR was statistically significant (p<0.05). The statistic result observed in the next 2 weeks after stopping administration of omega-3 was also significant (p<0.05).
Conclusion: The results of the study showed that the omega-3 fatty acids can reduce IR. The greater the IR, the smaller the results for the same dose of omega-3. The effect of these fatty acids on IR continues after the end of treatment.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Deedwania P. Hypertension dyslipidemia and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β- blockers. J Clin Hypertens (Greenwich) 13: 52-59 2011.
2. Henry N. Ginsberg. Insulin resistance and cardiovascular disease. J Clin Invest 106: 453-458 2000.
3. Steinberger J Daniels SR American Heart Association Atherosclerosis Hypertension and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) et al. Obesity insulin resistance diabetes and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis Hypertension and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition Physical Activity and Metabolism). Circulation 107: 1448-1453 2003.
4. Sharpless JL. Polycystic ovary syndrome and the metabolic syndrome. Clinical Diabetes 21: 154-161 2003.
5. Ausk KJ Boyko EJ Ioannou GN. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care 33: 1179-1185 2010.
6. Lahiri SW. Management of type 2 diabetes: What is the next step after metformin? Clinical Diabetes 30: 72-75 2012.
7. Geroldi C Frisoni GB Paolisso G et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 62: 1067-1072 2005.
8. Bordel-Marchasson I Lapre E Laksir H Puget E. Insulin resistance diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 36: 173-181 2010.
9. Talbot K Wang HY Kazi H et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance IRS-1 dysregulation and cognitive decline. J Clin Invest 122: 1316-1338 2012.
10. Watson GS Craft S. Insulin resistance inflammation and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 245: 21-23 2006.
11. Fernanda G. De Felice Mychael V. Lourenco Sergio T. Ferreira. How does brain insulin resistance develop in Alzheimer's disease? Alzheimer’s Dement 10[1 Suppl]: S26-S32 2014.
12. Delarue J LeFoll C Corporeau C Lucas D. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 44: 289-299 2004.
13. Juárez-López C Klünder-Klünder M Madrigal-Azcárate A Flores-Huerta S. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatr Diabetes 14: 377-383 2013.
14. Pirillo A Catapano AL. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atheroscler Suppl 14: 237-242 2013.